口服紫杉醇制剂的研究进展  

Research progress in oral drug preparation of paclitaxel

作　　者：翟瑞东 刘哲鹏[1] 赵守进 ZHAI Rui-dong;LIU Zhe-peng;ZHAO Shou-jin(Shanghai University of Science and Technology,Shanghai 200093,China)

机构地区：[1]上海理工大学,上海200093

出　　处：《实用药物与临床》2022年第1期92-96,共5页Practical Pharmacy and Clinical Remedies

摘　　要：传统的紫杉醇制剂为注射剂,使用Cremophor-EL和乙醇以提高其溶解度,会导致严重的超敏反应、中性粒细胞减少等不良反应,给患者带来了极大的不便。尽管新一代的紫杉醇制剂Abraxane不含Cremophor-EL和乙醇,但是仍需要通过频繁的静脉输注来实现治疗,并且制备与保存过程极其昂贵。口服给药是最常用的给药途径,与静脉给药相比,口服给药可以使患者自行给药,降低了卫生保健成本并提高了患者依从性。因此口服紫杉醇具有巨大的开发价值与挑战性。本综述主要介绍了目前已经开发出的多种紫杉醇的口服给药递送系统以及口服紫杉醇的挑战。Objective Conventional paclitaxel preparations are injections that use Cremophor-EL and ethanol to improve their solubility,leading to severe hypersensitivity,neutropenia and other adverse reactions.This brings great inconvenience to the patients.The new generation of paclitaxel preparations-Abraxane is free of Cremophor-EL and ethanol,but still needs frequent intravenous infusion,and the preparation and preservation process is extremely expensive.Oral administration is the most commonly used route of drug administration.Compared with intravenous administration,oral administration can enable patients to take their own medicine,thus reducing the cost of health care and improving patient compliance.Therefore,oral paclitaxel has great development value and challenge.This review mainly introduces the oral delivery system of paclitaxel and the challenge of oral paclitaxel.

关 键 词：口服给药 紫杉醇 药物递送系统 

分 类 号：R943[医药卫生—药剂学]